Team


Screen Shot 2018-10-01 at 14.27.02.png

Terry McWade - CEO

Terry worked in the pharmaceutical industry with Servier Laboratories as Managing Director of Servier Denmark and previously in the Paris headquarters (1988-1992). He led the healthcare consulting practice in the London office of the Boston Consulting Group (1993-1999). As CEO of Exceptis Technologies, Terry led the sale of the business to Trintech Group (TTPA nasdaq) for $26m in 2000. Prior to establishing Valitacell Terry was Deputy CEO of the Royal College of Surgeons in Ireland (2002-2013). He is the former Chairman of the European Vaccine Initiative, Deputy Chairman of the Dublin Dental Hospital and serves on a number of committees of the Irish Medical Council. Terry trained as a medical doctor in Trinity College Dublin and holds an MBA from INSEAD.

 

Jerry Clifford - COO

Prior to establishing Valitacell Jerry worked as the Commercial Director of Technopath Ltd (2010-2014). In this role he initiated and defined the research programme with the University of Sheffield which led to the development of the Valitacell technologies and the associated IP. The Technopath Group grew significantly during his time there, including achieving a sole supplier contract with a major IVD company. A trade-sale exit of Technopath Distribution to Diploma Healthcare followed in September 2014. Prior to Technopath Jerry was Vice President for Development at the Institute of Technology Tralee. He is a founder and a Non-Executive Director of Castel International, a provider of English Language and concierge services to a number of Irish universities and medical training colleges. Jerry trained as neuroscientist and holds a PhD from RCSI and an MBA from UCC.

 
 

David James - CSO

The Scientific Advisory Board for Valitacell is chaired by Prof. David James of the University of Sheffield. David graduated in 1989 from King ́s College London with a Ph.D. in Biochemistry, followed by postdoctoral research in Wye College (University of London), then the University of Kent; the latter a joint project with the Advanced Centre for Biochemical Engineering at University College London. He moved to the University of Queensland in 2001 as an Associate Professor of Bioengineering, then Professorial Research Fellow in the Australian Institute of Bioengineering and Nanotechnology. David was appointed Chair in Bioprocess Engineering at Sheffield in 2006 with a Royal Society Wolfson Research Merit Award "Research and Training in Biopharmaceutical Bioprocessing for UK Bioindustry". 

 
Screen Shot 2017-10-06 at 16.59.53.png
 

Ben Thompson - Head of Data 

Ben is an extremely experienced cell line development scientist with a unique combination of education and expertise in bioprocess engineering, mathematics and statistics. Ben has been centrally involved in all Valitacell product innovations since inception and is a co- inventor of Valitacell IP. 

 

Carolanne Doherty - Marketing & Sales Manager

Carolanne is a design and sales focused scientist with a PhD in Molecular and Computational Biology spanning hypothesis testing in complex systems biology to rational impact dissemination of the results. Prior to joining Valitacell, Carolanne was the project manager with the School of Medicine UCD, developing health-tech apps to improve global primary healthcare in Africa and she led a pilot clinical study on type 2 diabetes in Malawi. Carolanne holds a PhD in Systems Biology from Systems Biology Ireland in University College Dublin, and an MSc in Science Communication from UWE in Bristol, UK.

 
Screen Shot 2017-12-14 at 09.25.57.png

Hannah Byrne - Product Manager

Hannah is a Product Manager at Valitacell responsible for developing the product strategy for ValitaTITER. Prior to joining Valitacell, Hannah held the position of Research Scientist at Kymab, a biotechnology company based in Cambridge U.K. During her time at Kymab, Hannah initially worked in technology development, where her main focus was on the construction of their bispecific antibody generation platform before making the transition into bio-analytics, formulation and project leadership. Hannah holds a PhD in Biochemistry from Dublin City University. 

 
Screen Shot 2017-12-15 at 10.07.43.png

Karen Coss - Product Manager

Karen is a Product Manager at Valitacell, responsible for the development of the ValitaQC platform. Prior to joining Valitacell, Karen was a Research Associate at King’s College London, in the department of infectious diseases. During this time, Karen studied the glycosylation of HIV-1 during infection with an application towards vaccine design. Karen holds a PhD in Translational Medicine from University College Dublin, where she used genomic and glycomic approaches to develop antibody biomarkers to monitor patients with rare metabolic disorders.

 
Screen Shot 2017-12-13 at 16.50.54.png

Stephanie Davies - Product Development Specialist

Stephanie is a product development scientist working on the application of Valitacell technology into new areas, with particular focus on the ChemStress fingerprinting platform with application in cell therapy and exosome production. Stephanie holds a PhD in Molecular Cell Biology from University College Cork and has experience in design and optimisation of cell-based systems. 

 
Screen Shot 2017-12-15 at 10.08.00.png

Jonathan Cawley - Product Development Scientist

Jonathan is a Product Development Scientist at Valitacell with a particular emphasis in enabling cell line selection based on desirable glycosylation profiles. Prior to joining Valitacell he completed his PhD in Biotechnology at Dublin City University. His thesis described the use of recombinant lectin probes for investigating CHO cell surface glycosylation. He is experienced in protein purification, CHO cell culture, molecular biology and glycan analysis. He co-authored a book chapter entitled ‘Lectin Affinity Chromatography’ published in 2017 in Protein Chromatography. He completed his PhD in 2017.

 
Screen Shot 2018-07-03 at 11.24.54.png

Paul Dobson - Data Scientist

Paul has wide-ranging experience at the interface between biotechnology, computer science and engineering. With a long track record of using informatics and modelling to advance the fundamental understanding of drug action and cell function, Paul applies his unique experience to drive drug discovery and Industrial Biotech cell and process design for biomanufacturing. He has worked in major interdisciplinary academic research groups and previously led his own biomanufacturing research group at The University of Sheffield.


Scientific Board

 
Screen Shot 2018-09-28 at 13.31.20.png
 

David James - CSO

The Scientific Advisory Board for Valitacell is chaired by Prof. David James of the University of Sheffield. David graduated in 1989 from King ́s College London with a Ph.D. in Biochemistry, followed by postdoctoral research in Wye College (University of London), then the University of Kent; the latter a joint project with the Advanced Centre for Biochemical Engineering at University College London. He moved to the University of Queensland in 2001 as an Associate Professor of Bioengineering, then Professorial Research Fellow in the Australian Institute of Bioengineering and Nanotechnology. David was appointed Chair in Bioprocess Engineering at Sheffield in 2006 with a Royal Society Wolfson Research Merit Award "Research and Training in Biopharmaceutical Bioprocessing for UK Bioindustry". 

 
Screen Shot 2018-09-28 at 13.31.36.png

Frank Barry - Scientific Advisor

Prof. Frank Barry is Scientific Director of the Regenerative Medicine Institute (REMEDI) and Director of the National Centre for Biomedical Engineering Science (NCBES) at NUI Galway. He is an internationally renowned stem cell researcher with a particular research interest in the therapeutic application of adult stem cells, especially mesenchymal stem cells (MSCs) from bone marrow. For over 10 years he has directed a series of research programmes focusing on the isolation and characterization of adult stem cells, and on the development of methods for their delivery in a variety of clinical indications.  He has also developed approaches for the use of MSCs for the delivery of specific therapeutic genes, for example in rheumatoid arthritis. In addition he has an interest in proteomics and mass spectrometry for the identification of surface molecules on cells.


Board

Screen Shot 2018-10-02 at 06.20.55.png

Malcolm Bell - Non-executive Director

Malcolm co-founded Technopath Clinical Diagnostics in 2004 and was appointed CEO in 2011. He has successfully co-founded, developed and exited a number of life science and healthcare businesses based on novel technology and drawing on his over 20 years’ experience in these sectors. Malcolm brings extensive sales experience to the Company based on his strong scientific background. Malcolm identified the market need and initially led the project to develop the Valitacell technology. Previously, Malcolm was the co-founder and Joint Managing Director of Technopath (Distribution) which is now part of the Diploma plc group. Malcolm was educated at the National University of Ireland and holds a B.Sc. Honours degree in Molecular Biology and a Master's Degree in Biotechnology.

 
Screen Shot 2018-10-01 at 14.30.24.png

Jerry Clifford - COO

Prior to establishing Valitacell Jerry worked as the Commercial Director of Technopath Ltd (2010-2014). In this role he initiated and defined the research programme with the University of Sheffield which led to the development of the Valitacell technologies and the associated IP. The Technopath Group grew significantly during his time there, including achieving a sole supplier contract with a major IVD company. A trade-sale exit of Technopath Distribution to Diploma Healthcare followed in September 2014. Prior to Technopath Jerry was Vice President for Development at the Institute of Technology Tralee. He is a founder and a Non-Executive Director of Castel International, a provider of English Language and concierge services to a number of Irish universities and medical training colleges. Jerry trained as neuroscientist and holds a PhD from RCSI and an MBA from UCC.

 
Screen Shot 2018-10-01 at 14.27.02.png

Terry McWade - CEO

Terry worked in the pharmaceutical industry with Servier Laboratories as Managing Director of Servier Denmark and previously in the Paris headquarters (1988-1992). He led the healthcare consulting practice in the London office of the Boston Consulting Group (1993-1999). As CEO of Exceptis Technologies, Terry led the sale of the business to Trintech Group (TTPA nasdaq) for $26m in 2000. Prior to establishing Valitacell Terry was Deputy CEO of the Royal College of Surgeons in Ireland (2002-2013). He is the former Chairman of the European Vaccine Initiative, Deputy Chairman of the Dublin Dental Hospital and serves on a number of committees of the Irish Medical Council. Terry trained as a medical doctor in Trinity College Dublin and holds an MBA from INSEAD.

 
Screen Shot 2018-10-02 at 06.24.48.png

Dave Sullivan - Non-Executive Director

Co-founder of Technopath Group, and CEO of Technopath Distribution since 2011, David is an experienced CEO and sales and marketing professional with a demonstrated track record of identifying, launching and growing new product lines in the life sciences arena over his 25 year career. Since co-founding the company in 1997 he has consistently grown the business exponentially. An EY Entrepreneur of the Year Finalist, David has developed and launched a number of life science technologies and businesses. Earlier in his career David worked for Brennan & Company as Product Manager for Beckman DSG from 1989 and as Sales Manger for the Clinical Division from 1992-1998, managing major multinational brands including, Beckman DSG, Instrumentation Laboratory and Ortho Clinical Diagnostics. David is a Fellow of the Institute of Medical Laboratory Sciences, from University of the West of England in 1988, having previously graduated with a a Certificate and Diploma in Medical Laboratory Sciences from Cork Institute of Technology in 1984 and 1986 respectively.

 
Screen Shot 2018-10-02 at 06.26.21.png

Peter Thornton - Non-Executive Director

Peter is CFO and an investor in Technopath Clinical Diagnostics since 2014. He brings significant experience in the areas of finance, corporate development and M&A in both public and private life science companies. He most recently served as SVP Business Integration for Alkermes plc, SVP Corporate and Business Development for Elan Corporation plc and CFO of Agenus Inc., a NASDAQ-listed biotechnology company. Peter has served as a Director of both public and private companies including Merrion Pharmaceuticals plc, Cydex Pharmaceuticals Inc. and Agenus Inc. and is currently a director of Munich based drug delivery company Leon Nanodrugs Gmbh. Peter is a KPMG qualified Chartered Accountant and holds a Bachelor o f Commerce degree from University College Cork, Ireland.